ERBB2 and neoplasm: nab-PTX resulted in tumor shrinkage in 88.7% patients (except one unevaluable patient), with a clinical RR of 59.3% [(32/54), Fig. 3a, b], while the rate in HER2-positive patients was 77.2% [17/22; luminal/HER2, 82.4% (14/17); HER2-rich, 60% (3/5)] with TZ treatment (Fig. 3a, b).